TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06431971: Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease: A Randomized, Placebo-controlled, Double-blinded, Parallel 2-arm, With Open-label Extension Placebo-to-active Switch, Multi-ce

Sponsor: InnoMedica Schweiz AG · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,225,600

Rescue Site Savings

+$5,432,000

Unlock Full NCT06431971 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06431971 Rescue Dossier →